Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates

A compound of formula (I):

• or stereoisomers, racemic mixtures, tautomers, pharmaceutically acceptable salts, thereof;
• wherein
• A is selected from the group consisting of
• wherein
• can be attached to the N atom at any available position, and wherein
• is substituted by one or more substituents Rj;
• B is selected from the group consisting of O and NRa;
• E and V are independently selected from the group consisting of N, NR5, O and S;
• G is selected from the group consisting of a benzene ring and a pyridine ring;
• J is selected from the group consisting of O, N—R1 and CH2 or J is selected from the group consisting of CH or C if J is attached to R2;
• Y, Y1, Y2 and Y3 are CZ;
• Z is independently selected from the group consisting of H, halogen, O-alkyl, alkyl and CN;
• R is independently selected from the group consisting of
• and —NR3R4;
• Ra is selected from the group consisting of H and alkyl;
• Rd, Re, Rf, and Rg are independently selected from the group consisting of H and alkyl, or any two of Rd, Re, Rf, and Rg may be joined to form a 3 to 8-membered ring;
• Rj is independently selected from the group consisting of -halogen, —O-alkyl, —NR3R4, —CN,
• wherein a C1-2 carbon atom-containing bridge or a bond can be present between the a carbon atom and the c or d carbon atom or wherein a C1-2 carbon atom-containing bridge or a bond can be present between the b carbon atom and the c or d carbon atom;
• R1 is selected from the group consisting of H and alkyl;
• R2 is independently selected from the group consisting of alkyl, or —O-alkyl and wherein if two R2 are geminal they can be joined to form a 3 to 6-membered ring;
• R3 and R4 are independently selected from the group consisting of H and alkyl;
• R5 is selected from the group consisting of H and alkyl;
• n is 0, 1, 2, 3 or 4;
• r and s are independently 0, 1, 2 or 3;
• and
• t and u are independently 1, 2 or 3.